日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia.

虾青素是一种天然抗氧化剂,可以降低糖尿病前期和血脂异常患者的胆固醇和心血管风险指标

Ciaraldi Theodore P, Boeder Schafer C, Mudaliar Sunder R, Giovannetti Erin R, Henry Robert R, Pettus Jeremy H

Author Correction: Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity

作者更正:载脂蛋白J是一种肝脏因子,调节肌肉葡萄糖代谢和胰岛素敏感性。

Seo, Ji A; Kang, Min-Cheol; Yang, Won-Mo; Hwang, Won Min; Kim, Sang Soo; Hong, Soo Hyun; Heo, Jee-In; Vijyakumar, Achana; de Moura, Leandro Pereira; Uner, Aykut; Huang, Hu; Lee, Seung Hwan; Lima, Inês S; Park, Kyong Soo; Kim, Min Seon; Dagon, Yossi; Willnow, Thomas E; Aroda, Vanita; Ciaraldi, Theodore P; Henry, Robert R; Kim, Young-Bum

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors

关于使用钠-葡萄糖协同转运蛋白(SGLT)抑制剂治疗的1型糖尿病患者发生糖尿病酮症酸中毒的风险管理的国际共识

Danne, Thomas; Garg, Satish; Peters, Anne L; Buse, John B; Mathieu, Chantal; Pettus, Jeremy H; Alexander, Charles M; Battelino, Tadej; Ampudia-Blasco, F Javier; Bode, Bruce W; Cariou, Bertrand; Close, Kelly L; Dandona, Paresh; Dutta, Sanjoy; Ferrannini, Ele; Fourlanos, Spiros; Grunberger, George; Heller, Simon R; Henry, Robert R; Kurian, Martin J; Kushner, Jake A; Oron, Tal; Parkin, Christopher G; Pieber, Thomas R; Rodbard, Helena W; Schatz, Desmond; Skyler, Jay S; Tamborlane, William V; Yokote, Koutaro; Phillip, Moshe

Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?

2 型糖尿病心血管结局试验:对临床实践意味着什么?

Eckel, Robert H; Farooki, Azeez; Henry, Robert R; Koch, Gary G; Leiter, Lawrence A

A Pilot Study to Assess Clinical Utility and User Experience of Professional Continuous Glucose Monitoring Among People With Type 2 Diabetes

一项评估专业连续血糖监测在2型糖尿病患者中的临床实用性和用户体验的试点研究

Midyett, Kurt; Unger, Jeffrey R; Wright, Eugene E; Daniel, Timothy D; Kruger, Davida F; Henry, Robert R; Hegazi, Refaat A

SGLT inhibitor adjunct therapy in type 1 diabetes

SGLT抑制剂辅助治疗1型糖尿病

McCrimmon, Rory J; Henry, Robert R

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial

达格列净对2型糖尿病患者24小时血糖控制的影响:一项随机对照试验

Henry, Robert R; Strange, Poul; Zhou, Rong; Pettus, Jeremy; Shi, Leon; Zhuplatov, Sergey B; Mansfield, Traci; Klein, David; Katz, Arie

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial

在 2 型糖尿病合并混合型血脂异常患者中,阿利西尤单抗与常规降脂治疗作为他汀类药物附加疗法的比较:ODYSSEY DM-DYSLIPIDEMIA 随机试验

Ray, Kausik K; Leiter, Lawrence A; Müller-Wieland, Dirk; Cariou, Bertrand; Colhoun, Helen M; Henry, Robert R; Tinahones, Francisco J; Bujas-Bobanovic, Maja; Domenger, Catherine; Letierce, Alexia; Samuel, Rita; Del Prato, Stefano

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials

阿利西尤单抗对无糖尿病代谢综合征患者血脂和脂蛋白的影响:来自 10 项 3 期试验的汇总数据

Henry, Robert R; Müller-Wieland, Dirk; Taub, Pam R; Bujas-Bobanovic, Maja; Louie, Michael J; Letierce, Alexia; Ginsberg, Henry N

Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial

胰高血糖素受体抗体(REMD-477)对1型糖尿病的影响:一项随机对照试验

Pettus, Jeremy; Reeds, Dominic; Cavaiola, Tricia S; Boeder, Schafer; Levin, Michelle; Tobin, Garry; Cava, Edda; Thai, Dung; Shi, Jim; Yan, Hai; Bautista, Edgar; McMillan, John; Unger, Roger; Henry, Robert R; Klein, Samuel